Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Central to Cassava's hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Researchers have demonstrated that mutations that cause familial AD, amyloid beta-40, and -42 production is more likely to be reduced or abolished due to decreased enzymatic activity of gamma-secretase.

Cassava Sciences' Hypothesis Raises Doubts

Corcept Therapeutics

Novo Nordisk

Regeneron Pharmaceuticals

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

4 Top Biotech Stocks To Watch This Week

AerSale Corp

BriaCell Therapeutics 

Big 5 Sporting Goods

Progenity

Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report

On Nov 4, Cassava Sciences issued a PR which headline reads, 'Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' And the sub-heading: It states, "No evidence of data manipulation was found for Western blot data."

Cassava Sciences: A Close Look

Airbnb

AMC Entertainment

Expedia

Lyft

Peloton

Uber

Zillow

Stocks continued their run of near daily record highs heading into November, as investors digested a slew of economic updates and earnings reports.

Stocks Heading Into Holiday Season With Record Highs

Cortexyme Inc

Anavex Life Sciences

Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.

Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) surged 48.96% today. This is why it happened.

Cassava Sciences (SAVA) Stock: Why The Price Surged Today

Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheimer's disease.  The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company's lead Alzheimer's candidate.

Why Did Cassava Sciences Stock Jump 49% Today?

Cassava Sciences Inc (NASDAQ:SAVA) is soaring today, up 46.1% to trade at $82.80 at last glance, after the company said the Journal of Neuroscience found no evidence of data manipulation in its 2012 article describing a new approach to treating Alzheimer's.

Cassava Sciences Stock Surges on Alzheimer's Article Update

Cassava Sciences: Major Hit To The Bears

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've never doubted the integrity of our people or science," said Remi Barbier, President & CEO.

Why Cassava Sciences Shares Are Rising

Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.

SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today

It states, “No evidence of data manipulation was found for Western blot data.” It states, “No evidence of data manipulation was found for Western blot data.”

Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' Lead Drug Candidate

On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares plunged more than 7% after Quintessential Capital management released a report saying the stock is worthless. The firm called for shorts to swoop in claiming its Alzheimer's drug Simufilam seems to be based on forged research.

Is it too risky to buy Cassava Sciences as Quintessential says the stock is worthless?

Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds. The post Cassava Sciences Is on a Bumpy Road to Multibagger Status appeared first on InvestorPlace.

Cassava Sciences Is on a Bumpy Road to Multibagger Status

As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining. The post SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher appeared first on InvestorPlace.

SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher

Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such as StockTwits throughout the day.

What's Up With Cassava Sciences Flying Today?

Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.

Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?

Cassava Sciences, Inc. is a pre-revenue biotechnology company. The company specializes in neurodegenerative diseases, such as Alzheimer's disease.

Cassava Sciences Stock: Massive Potential Marred By Controversy

Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.

Cassava Stock Could Jump More Than 200 Times

Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run.

Cassava Sciences' Stock Remains an Enigma

There's no way to mitigate its high risk nature completely. But if you're bullish on Simulfilam?

Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along

SAN DIEGO & AUSTIN, Texas--(BUSINESS WIRE)---- $SAVA #Alzheimers--Cassava Sciences, Inc. (SAVA) Accused of Falsely Touting the Viability and Efficacy of its Lead Drug Candidate

SHAREHOLDER ALERT: Robbins LLP Investigates Cassava Sciences, Inc. (SAVA) on Behalf of Shareholders

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Western District of Texas captioned Rao v. Cassava Sciences, Inc., et al., (Case No. 1:21-cv-00971) on behalf of persons and entities that purchased or otherwise acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities, and/or sold (wrote) Cassava put options, between September 14, 2020 and August 27,

News for Cassava Sciences Inc Stock (SAVA)